- Home
- BMHL vs ANVS Comparison
BMHL vs ANVS Comparison
Compare BMHL & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMHL | ANVS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 111.3M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMHL | ANVS |
|---|---|---|
| Price | $3.66 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 4.2K | ★ 520.5K |
| Earning Date | 03-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $6,873,097.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $67.77 | ★ N/A |
| Revenue Growth | ★ 66.02 | N/A |
| 52 Week Low | $2.72 | $1.11 |
| 52 Week High | $4.49 | $5.50 |
Technical Indicators
Market Signals| Indicator | BMHL | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 32.52 |
| Support Level | $3.20 | $2.42 |
| Resistance Level | $3.72 | $2.81 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 69.70 | 5.27 |
Price Performance
Historical ComparisonAbout BMHL Bluemount Holdings Limited Class B Ordinary Shares
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.